Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Nycomed Buys Majority Stake in Guangdong Techpool Bio-Pharma

publication date: Nov 1, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Swiss biopharma Nycomed bought a majority 51.3% of Guangdong Techpool Bio-Pharma, saying the acquisition will increase its activity in China. Although the price was not announced officially, a Nycomed spokesperson said the company paid $210 million, according to Reuters. Both companies are privately owned, but Nycomed has stated its intention of staging an IPO sometime soon. More details....

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...